| Identification | More | [Name]
Sodium dihydrogenorthophosphate | [CAS]
7558-80-7 | [Synonyms]
acidsodiumphosphate
monosodiumdihydrogenorthophosphate
monosodiumhydrogenphosphate
monosodiumphosphate(sodiumdihydrogen
monosodiumphosphate(sodiumdihydrogenphosphate)
monosorbxp-4
phosphatemonobasiquedesodium
Phosphoricacid,monosodiumsalt
primarysodiumphosphate
sodiumbiphosphateanhydrous
sodiumdihydrogenmonophosphate
sodiumdihydrogenphosphate(1:2:1)
sodiumdihydrogenphosphate(nah2po4)
Sodiumdihydrogenphosphate,an
sodiumdihydrogenphosphateanhydrous
sodiummonobasicphosphate(nah2po4)
sodiumorthophosphate,primary
sodiumphosphate(na(h2po4))
sodiumprimaryphosphate
SODIUM DIHYDROGEN PHOSPHATE-16O4 | [EINECS(EC#)]
231-449-2 | [Molecular Formula]
H2NaO4P | [MDL Number]
MFCD04113752 | [Molecular Weight]
119.98 | [MOL File]
7558-80-7.mol |
| Chemical Properties | Back Directory | [Appearance]
White, slightly deliquescent crystals or granules. | [Melting point ]
<0°C | [Boiling point ]
100°C | [density ]
1.40 g/mL at 20 °C
| [vapor pressure ]
0Pa@20°C | [storage temp. ]
Store at RT. | [solubility ]
H2O: 5 M, clear, colorless
| [form ]
powder
| [color ]
White | [Odor]
at 100.00?%. odorless | [PH]
4.0 - 4.5 (25℃, 50g/L in water) | [pka]
(1) 2.15, (2) 6.82, (3) 12.38 (at 25℃) | [Stability:]
Stable. Incompatible with heavy metals, strong acids. | [Water Solubility ]
Soluble in water. Insoluble in alcohol,ether and chloroform. | [Sensitive ]
Hygroscopic | [λmax]
λ: 260 nm Amax: ≤0.025
λ: 280 nm Amax: ≤0.02 | [Merck ]
14,8660 | [BRN ]
3903772 | [InChIKey]
AJPJDKMHJJGVTQ-UHFFFAOYSA-M | [LogP]
-2.148 (est) | [Uses]
Excipient. | [CAS DataBase Reference]
7558-80-7(CAS DataBase Reference) | [EPA Substance Registry System]
7558-80-7(EPA Substance) |
| Safety Data | Back Directory | [Hazard Codes ]
Xi | [Risk Statements ]
R36/37/38:Irritating to eyes, respiratory system and skin . | [Safety Statements ]
S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice .
S36:Wear suitable protective clothing . | [WGK Germany ]
1
| [RTECS ]
WA1900000
| [F ]
3 | [TSCA ]
Yes | [HS Code ]
28352200 | [Safety Profile]
Poison by intramuscular route. Mdly toxic by ingestion. A human and experimental eye irritant. When heated to decomposition it emits toxic fumes of POx and Na2O. See also PHOSPHATES. | [Hazardous Substances Data]
7558-80-7(Hazardous Substances Data) | [Toxicity]
LD50 orally in Rabbit: 8290 mg/kg LD50 dermal Rabbit > 7940 mg/kg |
| Questions and Answers (Q&A) | Back Directory | [Chemical Properties]
Anhydrous salt: white crystalline powder; slightly hygroscopic; forms sodium acid pyrophosphate, Na2H2P2O7 on heating above 225°C and sodium metaphosphate (NaPO3)n at about 350 to 400°C; very soluble in water, aqueous solution acidic.
Monohydrate: white orthorhombic crystals or granules; density 2.04 g/cm3 ; loses its water of crystallization at 100°C; very soluble in water, pH of 1% solution 4.5; insoluble in alcohol.
Dihydrate: large transparent crystals; orthorhombic bisphenoidal structure; density 1.915 g/cm 3 ; decomposes at 60°C; very soluble in water; insoluble in alcohol.
| [Uses]
Sodium phosphate monobasic is used in baking powders, acid cleansers, electroplating, as a dry acidulant, and in treating boiler water. It also is a nutrient supplement in food. It is a laboratory reagent used as a buffer.
| [Preparation]
Sodium phosphate monobasic can be prepared by partial neutralization of phosphoric acid with sodium hydroxide in equimolar amounts:
H3PO4+ NaOH →NaH2PO4+ H2O
It also can be made by treating disodium hydrogen phosphate with phosphoric acid in proper stoichiometric amount:
Na2HPO4+ H3PO4→2NaH2PO4
|
| Hazard Information | Back Directory | [Physical properties]
Anhydrous salt: white crystalline powder; slightly hygroscopic; forms sodium acid pyrophosphate, Na2H2P2O7 on heating above 225°C and sodium metaphosphate (NaPO3)n at about 350 to 400°C; very soluble in water, aqueous solution acidic.
Monohydrate: white orthorhombic crystals or granules; density 2.04 g/cm3; loses its water of crystallization at 100°C; very soluble in water, pH of 1% solution 4.5; insoluble in alcohol.
Dihydrate: large transparent crystals; orthorhombic bisphenoidal structure; density 1.915 g/cm3; decomposes at 60°C; very soluble in water; insoluble in alcohol. | [Definition]
ChEBI: Sodium dihydrogenphosphate is a sodium phosphate. | [Production Methods]
Monobasic sodium phosphate is prepared by adding phosphoric
acid to a hot, concentrated solution of disodium phosphate until the
liquid ceases to form a precipitate with barium chloride. This solution is then concentrated and the monobasic sodium phosphate
is crystallized. | [General Description]
Sodium phosphate monobasic is an effective oral osmotic laxative at minimal concentration. It is used for colonic cleansing before endoscopic examination of colon. | [Flammability and Explosibility]
Nonflammable(100%) | [Pharmaceutical Applications]
Monobasic sodium phosphate is used in a wide variety of
pharmaceutical formulations as a buffering agent and as a
sequestering agent. Therapeutically, monobasic sodium phosphate
is used as a mild saline laxative and in the treatment of hypophosphatemia.
Monobasic sodium phosphate is also used in food products, for
example, in baking powders, and as a dry acidulant and
sequestrant. | [Safety]
Monobasic sodium phosphate is widely used as an excipient in
parenteral, oral, and topical pharmaceutical formulations.
Phosphate occurs extensively in the body and is involved in
many physiological processes since it is the principal anion of
intracellular fluid. Most foods contain adequate amounts of
phosphate, making hypophosphatemia virtually unknown except
in certain disease states or in patients receiving total parenteral
nutrition. Treatment is usually by the oral administration of up to
100 mmol of phosphate daily.
Approximately two-thirds of ingested phosphate is absorbed
from the gastrointestinal tract, virtually all of it being excreted in the
urine, and the remainder is excreted in the feces.
Excessive administration of phosphate, particularly intravenously,
rectally, or in patients with renal failure, can cause
hyperphosphatemia that may lead to hypocalcemia or other severe
electrolyte imbalances. Adverse effects occur less frequently
following oral consumption, although phosphates act as mild saline
laxatives when administered orally or rectally (2–4 g of monobasic
sodium phosphate in an aqueous solution is used as a laxative).
Consequently, gastrointestinal disturbances including diarrhea,
nausea, and vomiting may occur following the use of monobasic
sodium phosphate as an excipient in oral formulations. However,
the level of monobasic sodium phosphate used as an excipient in a pharmaceutical formulation is not usually associated with adverse
effects.
LD50 (rat, IM): 0.25 g/kg(10)
LD50 (rat, oral): 8.29 g/kg | [storage]
Monobasic sodium phosphate is chemically stable, although it is
slightly deliquescent. On heating at 100°C, the dihydrate loses all of
its water of crystallization. On further heating, it melts with
decomposition at 205℃, forming sodium hydrogen pyrophosphate,
Na2H2P2O7. At 250℃ it leaves a final residue of sodium
metaphosphate, NaPO3.
Aqueous solutions are stable and may be sterilized by autoclaving.
Monobasic sodium phosphate should be stored in an airtight
container in a cool, dry place. | [Incompatibilities]
Monobasic sodium phosphate is an acid salt and is therefore
generally incompatible with alkaline materials and carbonates;
aqueous solutions of monobasic sodium phosphate are acidic and
will cause carbonates to effervesce.
Monobasic sodium phosphate should not be administered
concomitantly with aluminum, calcium, or magnesium salts since
they bind phosphate and could impair its absorption from the
gastrointestinal tract. Interaction between calcium and phosphate,
leading to the formation of insoluble calcium phosphate precipitates,
is possible in parenteral admixtures. | [Regulatory Status]
GRAS listed. Accepted for use as a food additive in Europe.
Included in the FDA Inactive Ingredients Database (injections;
infusions; ophthalmic, oral, topical, and vaginal preparations).
Included in nonparenteral and parenteral medicines licensed in the
UK. Included in the Canadian List of Acceptable Non-medicinal
Ingredients. |
|
|